Le Lézard
Classified in: Health, Business
Subject: PER

Leerink Partners Adds Industry Veteran Andrew Gitkin to Healthcare Investment Banking Team


BOSTON, April 25, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, today announced the addition of Andrew Gitkin as Senior Managing Director, Investment Banking. Mr. Gitkin brings over 25 years of experience in healthcare investment banking, specializing in mergers and acquisitions with a focus on ophthalmology and robotic surgery. Mr. Gitkin will be based in the firm's Miami office and will report to Dr. Dan Dubin, Global Co-Head of Investment Banking.

"Andrew's expertise in M&A advisory for ophthalmology and robotic surgery companies positions him as a valuable asset to our team and our clients," stated Dr. Dan Dubin, Global Co-Head of Investment Banking."

Prior to joining Leerink Partners, Mr. Gitkin served as a Senior Managing Director and Vice Chairman at Raymond James & Associates, co-leading the U.S. healthcare investment banking group. Previous to his role at Raymond James, Mr. Gitkin served as Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company. Prior to working at PiperJaffray, he honed his M&A expertise in the pharmaceutical, biotechnology, medical device, and diagnostic sectors at Moelis & Company.

Mr. Gitkin shared, "I am thrilled to join the Leerink team and share in their commitment to achieve the highest levels of success for our clients. I am eager to leverage my expertise with our clients to enhance the firm's distinguished reputation for excellence."

To learn more, visit: https://www.leerink.com/.

About Leerink Partners
Leerink Partners is a highly specialized healthcare investment bank with a legacy of excellence in the financial industry. The firm's experienced team delivers innovative advisory solutions, capital raising expertise, and unique insights to empower clients to achieve their strategic objectives. Since inception, the firm has helped clients raise over $160 billion and has established itself as a trusted partner to healthcare companies and their investors. The firm is a broker-dealer registered with the United States Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority.

Leerink Partners
Contact: Diane Vieira
(617) 918-4097

Prosek Partners for Leerink Partners
Contact: Michael Schutsky
(646) 818-9251

 

SOURCE Leerink Partners


These press releases may also interest you

at 14:42
Consumer M&A: Examining Challenges and Insights in Today's Market
Investor sentiment related to global supply chain risk and channel optimization has recently shifted. Growing geopolitical tensions between the U.S. and China and significant underperformance by high profile eCommerce businesses have caused investors...

at 14:36
Blue Cross Blue Shield of Massachusetts Celebrates National Bike Month and Supports Women's Wellness with Free Bluebikes Credits in May
Blue Cross Blue Shield of Massachusetts ("Blue Cross") today announced a new initiative aimed at supporting women's health in Greater Boston through...

at 14:30
TMX Group Consolidated Trading Statistics - April 2024
TMX Group Limited today announced April 2024 trading statistics for its marketplaces ? Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange (Alpha), including Alpha-X & Alpha DRK, and Montréal Exchange (MX). All TMX Equities...

at 14:30
EREZ ASSET MANAGEMENT RESPONDS TO FALSE ACCUSATIONS IN WHITESTONE REIT'S PRESS RELEASE
Reiterates the Need for Change at Whitestone, the Shopping Center REIT that Trades at the Biggest Discount to NAV of its Cited Peers Notes the Irony of a Board Filled with Undisclosed Former Service Providers to Mr. Mastandrea Claiming that One Call...

at 14:19
Optimizely Named a Leader in B2B Commerce Solutions
Optimizely, the leading digital experience platform (DXP) provider, today announced it has been named a Leader in The Forrester Wavetm: Commerce Solutions for B2B, Q2 2024. In this evaluation, Optimizely was recognized for its strong testing and...

at 14:18
The Board of Loomis has resolved to continue to repurchase shares
The Board of Directors of Loomis AB has resolved to repurchase shares by virtue of the authorization granted by the Annual General Meeting 2024. The repurchase may commence on May 7, 2024, end not later than on June 24, 2024, and comprise an amount...

More news about Business...


News published on and distributed by: